Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Molecular Templates, Inc.
Molecular Templates, Inc. News
Dec 19, 2024 - globenewswire.com
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
Dec 2, 2024 - globenewswire.com
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
Molecular Templates, Inc. Quantitative Score
About Molecular Templates, Inc.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Molecular Templates, Inc. Earnings & Revenue
Molecular Templates, Inc. Financials
Table Compare
Compare MTEM metrics with: | |||
|---|---|---|---|
Earnings & Growth | MTEM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MTEM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MTEM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MTEM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Molecular Templates, Inc. Income
Molecular Templates, Inc. Balance Sheet
Molecular Templates, Inc. Cash Flow
Molecular Templates, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Molecular Templates, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Molecular Templates, Inc. Executives
| Name | Role |
|---|---|
| Dr. Eric E. Poma Ph.D. | Interim Chief Financial Officer, Treasurer, Principal Acc. Officer, Chief Executive Officer, Chief Scientific Officer & Director |
| Dr. Grace Kim Ph.D. | Chief Strategy Officer & Head of IR |
| Ms. Kristen Quigley B.A. | Chief Operating Officer |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President & General Counsel |
| Dr. Joseph Phillips Ph.D. | Senior Vice President & Head of CMC Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Eric E. Poma Ph.D. | Interim Chief Financial Officer, Treasurer, Principal Acc. Officer, Chief Executive Officer, Chief Scientific Officer & Director | 1972 | 723.81K | |
| Dr. Grace Kim Ph.D. | Chief Strategy Officer & Head of IR | -- | ||
| Ms. Kristen Quigley B.A. | Chief Operating Officer | Female | 1971 | -- |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President & General Counsel | -- | ||
| Dr. Joseph Phillips Ph.D. | Senior Vice President & Head of CMC Development | -- |
Molecular Templates, Inc. Insider Trades
| Date | 14 Nov |
| Name | BIOTECH TARGET N V |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1279820 |
| Date | 27 Sep |
| Name | LALANDE KEVIN M. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1000 |
| Date | 27 Sep |
| Name | Gruia Gabriela |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1000 |
| Date | 27 Sep |
| Name | SELICK HAROLD E |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1000 |
| Date | 27 Sep |
| Name | HOFFMANN DAVE |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Nov | BIOTECH TARGET N V | 10 percent owner | Disposed | S-Sale | 1279820 |
| 27 Sep | LALANDE KEVIN M. | Director, 10 percent owner | Acquired | A-Award | 1000 |
| 27 Sep | Gruia Gabriela | Director | Acquired | A-Award | 1000 |
| 27 Sep | SELICK HAROLD E | Director | Acquired | A-Award | 1000 |
| 27 Sep | HOFFMANN DAVE | Director | Acquired | A-Award | 1000 |